Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates

Abstract Triple negative breast cancer (TNBC) accounts for about a fifth of all breast cancers and includes a diverse group of cancers. The heterogeneity of TNBC and the lack of target receptors on the cell surface make it difficult to develop specific therapeutic treatments. These aspects cause the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gloria Bertoli, Claudia Cava, Fabio Corsi, Francesca Piccotti, Cristina Martelli, Luisa Ottobrini, Valentina Vaira, Isabella Castiglioni
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/55a1477ce51945d6b0c6006989afd3e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55a1477ce51945d6b0c6006989afd3e2
record_format	dspace
spelling	oai:doaj.org-article:55a1477ce51945d6b0c6006989afd3e22021-12-02T16:36:11ZTriple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates10.1038/s41598-021-85746-w2045-2322https://doaj.org/article/55a1477ce51945d6b0c6006989afd3e22021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85746-whttps://doaj.org/toc/2045-2322Abstract Triple negative breast cancer (TNBC) accounts for about a fifth of all breast cancers and includes a diverse group of cancers. The heterogeneity of TNBC and the lack of target receptors on the cell surface make it difficult to develop specific therapeutic treatments. These aspects cause the high negative prognosis of patients with this type of tumor. The analysis of the molecular profiles of TNBC samples has allowed a better characterization of this tumor, supporting the search for new reliable diagnostic markers. To this end, we have developed a bioinformatic approach to integrate networks of genes differentially expressed in basal breast cancer compared to healthy tissues, with miRNAs able to regulate their expression. We studied the role of these miRNAs in TNBC subtype cell lines. We therefore identified two miRNAs, namely miR-135b and miR-365, with a central role in regulating the altered functional pathways in basal breast cancer. These two miRNAs are differentially expressed in human TNBC immunohistochemistry-selected tissues, and their modulation has been shown to play a role in the proliferation of tumor control and its migratory and invasive capacity in TNBC subtype cell lines. From the perspective of personalized medicine, we managed to modulate the expression of the two miRNAs in organotypic cultures, suggesting their possible use as diagnostic and therapeutic molecules. miR-135b and miR-365 have a key role in TNBC, controlling proliferation and invasion. Their detection could be helpful in TNBC diagnosis, while their modulation could become a new therapeutic tool for TNBC.Gloria BertoliClaudia CavaFabio CorsiFrancesca PiccottiCristina MartelliLuisa OttobriniValentina VairaIsabella CastiglioniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gloria Bertoli Claudia Cava Fabio Corsi Francesca Piccotti Cristina Martelli Luisa Ottobrini Valentina Vaira Isabella Castiglioni Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
description	Abstract Triple negative breast cancer (TNBC) accounts for about a fifth of all breast cancers and includes a diverse group of cancers. The heterogeneity of TNBC and the lack of target receptors on the cell surface make it difficult to develop specific therapeutic treatments. These aspects cause the high negative prognosis of patients with this type of tumor. The analysis of the molecular profiles of TNBC samples has allowed a better characterization of this tumor, supporting the search for new reliable diagnostic markers. To this end, we have developed a bioinformatic approach to integrate networks of genes differentially expressed in basal breast cancer compared to healthy tissues, with miRNAs able to regulate their expression. We studied the role of these miRNAs in TNBC subtype cell lines. We therefore identified two miRNAs, namely miR-135b and miR-365, with a central role in regulating the altered functional pathways in basal breast cancer. These two miRNAs are differentially expressed in human TNBC immunohistochemistry-selected tissues, and their modulation has been shown to play a role in the proliferation of tumor control and its migratory and invasive capacity in TNBC subtype cell lines. From the perspective of personalized medicine, we managed to modulate the expression of the two miRNAs in organotypic cultures, suggesting their possible use as diagnostic and therapeutic molecules. miR-135b and miR-365 have a key role in TNBC, controlling proliferation and invasion. Their detection could be helpful in TNBC diagnosis, while their modulation could become a new therapeutic tool for TNBC.
format	article
author	Gloria Bertoli Claudia Cava Fabio Corsi Francesca Piccotti Cristina Martelli Luisa Ottobrini Valentina Vaira Isabella Castiglioni
author_facet	Gloria Bertoli Claudia Cava Fabio Corsi Francesca Piccotti Cristina Martelli Luisa Ottobrini Valentina Vaira Isabella Castiglioni
author_sort	Gloria Bertoli
title	Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
title_short	Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
title_full	Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
title_fullStr	Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
title_full_unstemmed	Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
title_sort	triple negative aggressive phenotype controlled by mir-135b and mir-365: new theranostics candidates
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/55a1477ce51945d6b0c6006989afd3e2
work_keys_str_mv	AT gloriabertoli triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT claudiacava triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT fabiocorsi triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT francescapiccotti triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT cristinamartelli triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT luisaottobrini triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT valentinavaira triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates AT isabellacastiglioni triplenegativeaggressivephenotypecontrolledbymir135bandmir365newtheranosticscandidates
_version_	1718383634641059840

Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates

Ejemplares similares